
Triumeq
Abacavir, Dolutegravir, Lamivudine
600/50/300mg
Abacavir, dolutegravir and lamivudine in one tablet, used in the management of HIV infection. Three agents against three stages of the viral cycle.
HIV targets CD4 immune cells and weakens immunity if untreated. Combination antiretroviral therapy can suppress the virus, protect health and prevent sexual transmission when an undetectable viral load is achieved and maintained.

Abacavir, Dolutegravir, Lamivudine
600/50/300mg
Abacavir, dolutegravir and lamivudine in one tablet, used in the management of HIV infection. Three agents against three stages of the viral cycle.

300/200mg
Tenofovir with emtricitabine as a 300/200mg film-coated tablet, for HIV infection and pre-exposure prophylaxis. Two reverse transcriptase inhibitors.

600 · 800mg
Darunavir 600mg and 800mg film-coated tablets, used in the management of HIV infection. A protease inhibitor that halts assembly of new virus.
The catalogue cannot diagnose HIV or define a regimen; specialist prescribing and viral-load, kidney, liver and interaction checks are required.
Possible early illness is non-specific and many people have no symptoms. Testing is appropriate after a potential exposure, during pregnancy and when certain infections occur. Tests have window periods; urgent post-exposure assessment should not wait for symptoms.
Regimens use medicines from different classes to maintain suppression. Lamivudine and dolutegravir are examples of components, not a universal combination. Monitoring confirms response and checks toxicity. See HIV management and antivirals for class context.
Seek urgent care for severe headache with stiff neck, confusion, seizures, major breathing difficulty, fainting, new weakness, persistent fever with marked illness or a severe rash after starting medicine. A recent high-risk exposure may qualify for time-sensitive post-exposure prophylaxis and needs immediate assessment.